Natco Pharma Board to Mull Agrochemicals Demerger on March 24

Introduction

Natco Pharma Limited has announced a pivotal board meeting scheduled for March 24, 2026, to deliberate on a significant corporate restructuring. The agenda focuses on a proposed scheme of arrangement to demerge its agrochemicals division into a new, wholly owned subsidiary named Natco Crop Health Sciences Limited. This strategic move, which first received in-principle approval in September 2025, aims to unlock value and streamline operations by creating two distinct, focused entities.

The Upcoming Board Meeting

The company's board of directors will convene to formally consider and approve the demerger plan. The proposal involves carving out the agrochemicals business on a going concern basis, meaning it will be transferred as a fully operational unit. The new entity, Natco Crop Health Sciences Limited, will function independently under the parent company's umbrella, allowing for dedicated management and tailored growth strategies.

Regulatory Compliance and Market Activity

In adherence to the Securities and Exchange Board of India (SEBI) regulations on insider trading, Natco Pharma has mandated a trading window closure. This restriction applies to all employees, connected persons, and their immediate relatives from March 19, 2026, to March 26, 2026. The trading window is set to reopen on March 27, 2026. This measure ensures fairness and prevents any potential misuse of price-sensitive information ahead of the board's decision. On the market front, shares of Natco Pharma closed at ₹957.90 on March 18, 2026, marking a gain of 1.59%, indicating positive investor sentiment leading up to the announcement.

Strategic Rationale for the Demerger

The proposal to separate the agrochemicals business stems from a strategic decision made by the board on September 25, 2025, when it gave its in-principle approval to evaluate the move. The primary objective is to unlock the intrinsic value of the core pharmaceutical operations while allowing the agrochemicals segment to pursue its own growth trajectory. Management believes this restructuring will provide greater operational flexibility, foster dedicated leadership for each business, and enable distinct brand positioning in their respective markets.

A Closer Look at the Agrochemicals Division

Natco Pharma's Crop Health Sciences division was established in 2019, focusing on the development and marketing of bioproducts and pesticides. While the division has shown potential, its performance was described as subdued in the fiscal year 2025, with revenues recorded at ₹60 crore. By spinning it off into a separate subsidiary, the company aims to provide the business with the focused resources and strategic direction needed to scale its operations and improve performance.

The Path to Restructuring

The journey toward this demerger began with the board's initial approval to explore the possibility in late 2025. This authorized the management to conduct a detailed evaluation, including determining the optimal capital and shareholding structure for the new entity. The upcoming meeting on March 24 represents the culmination of this evaluation process, where the board will review the comprehensive plan and make a formal decision. This step is crucial for reshaping the company's long-term corporate architecture.

Future Structure and Analyst Perspective

As part of the proposed arrangement, Natco Pharma may retain a small minority stake in Natco Crop Health Sciences Limited. This would facilitate continued support through shared services like research and development (R&D) and patent management, likely governed by Transitional Service Agreements (TSAs) at arm's length pricing. Analysts view this move as a logical step to enhance management focus on the core pharmaceutical business. However, they also note that the valuation at which the demerger is executed will be a critical factor for shareholders to monitor.

Conclusion

The board meeting on March 24 is a significant milestone for Natco Pharma as it moves closer to a strategic demerger of its agrochemicals business. The outcome will determine the future structure of the company and is expected to create two more agile and focused entities. Investors and market participants will be closely watching for the board's final approval and the subsequent details of the scheme of arrangement, which will be disclosed in accordance with regulatory requirements.